NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure.
NeoGenomics, Inc. (the “Company”) today announced that it has entered into a material definitive agreement to acquire Genoptix, Inc., a leading clinical oncology laboratory specializing in hematology and solid tumor testing, based in Carlsbad, California. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. In connection with this announcement, the Company has made available an Investor Presentation, which is attached to this Current Report on Form 8-K as Exhibit 99.2 and incorporated herein by reference. The Company presented this Investor Presentation during a scheduled web-cast and conference call to discuss the acquisition of Genoptix, Inc.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|
Item 7.01. |
Financial Statements and Exhibits. |
Exhibit Index
NEOGENOMICS INC ExhibitEX-99.1 2 a991pressrelease10232018.htm EXHIBIT 99.1 Exhibit Exhibit 99.1NeoGenomics Signs Definitive Agreement to Acquire GenoptixFt. Myers,…To view the full exhibit click here
About NEOGENOMICS, INC. (NASDAQ:NEO)
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.
